Radionuclide Production in the UK

This year, we were a proud sponsor of the third Radionuclide Production in the UK meeting in Manchester, co-hosted by Royal Society of Chemistry and National Physical Laboratory (NPL)!

Our Business Development Manager, Paul Adlem represented Cyclife Aquila Nuclear and was thrilled to witness firsthand the incredible momentum building in this vital sector!

The topics discussed at the event reinforced our confidence in the UK’s nuclear medicine future, examples include:

➡️ MRIP Programme translating investment into capability – Seeing tangible results like QMUL/Birmingham’s astatine-211 production breakthrough and NPL’s 225Ac advances demonstrates how GB funding is creating real domestic capacity.
➡️ The innovation ecosystem is maturing rapidly. From Bristol’s Proteus Project, developing compact accelerators, to UKAEA exploring fusion applications, the breadth of technical approaches gives us multiple pathways to success.
➡️ End-to-end supply chain visibility. Particularly impressed by presentations spanning fundamental research through to operational delivery (Sheffield’s Tc-99m regional network serving 10+ NHS hospitals shows what robust supply looks like).
➡️ True partnership models are emerging. The collaboration between research institutions, industry partners, clinical end-users and organisations like Cyclife Aquila Nuclear is creating the foundation for sustainable growth.

At Cyclife Aquila Nuclear, we understand that nuclear expertise extends far beyond traditional applications. Seeing researchers tackle everything from next-generation isotope production to separation technologies, reinforces why we are committed to supporting this sector’s development. Most significantly, this marks a shift from discussing potential to demonstrating progress toward genuine UK self-sufficiency in medical radionuclides.

We are proud to be part of an ecosystem driving such meaningful innovation in healthcare.